Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 7Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1GATA2 Deficiency 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5fludarabine 5Whole-Body Irradiation 4Busulfan 4Biopsy 4Specimen Handling 3Injections 3Cytarabine 3venetoclax 2decitabine and cedazuridine drug combination 2Tacrolimus 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporine 2CPX-351 2Azacitidine 2treosulfan 1peginterferon alfa-2b 1olutasidenib 1itacitinib 1canakinumab 1aldesleukin 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
102 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡